4 results
Primary: Period II (Week 8 to Week 16)1. To demonstrate the additional antihypertensive efficacy for seated diastolic blood pressure (SeDBP) gained by adding HCTZ 12.5 or 25 mg to the treatment regimen in subjects with moderate to severe HTN not…
To provide an answer to the following questions: 1. In patients with AD, does treatment with a ChEI improve cerebral hemodynamics? 2. Is there less progression of cerebrovascular lesions on follow-up of AD patients receiving ChEI*s? 3. Does this…
The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care